Investigational drug · Phase 3
UBT251
Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
10
8 still active
All registered trials
14
Any phase or sponsor naming "UBT251"
First trial start
2025
Mar 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "UBT251", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Obesity &Amp; Overweight
- Diabetes Mellitus, Type 2
- Obstructive Sleep Apnea
- Obstructive Sleep Apnea, Obesity
- Chronic Kidney Disease
- Obesity & Overweight
- Type 2 Diabetes
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Overweight
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Chronic kidney disease · MASH (fatty liver disease) · Cardiovascular and metabolic · Infectious disease and vaccines · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "UBT251" as an intervention, largest first.
- Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)Pivotal-lookingRecruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07653477 · 956 participants (planned) · Start Sep 7, 2026 · Primary completion Feb 29, 2028
Drug: UBT251 Injection 2.0 mg group; UBT251 Injection 4.0 mg group and 2 more · For: Type 2 Diabetes
Sites: Shanghai, China
- UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)Pivotal-lookingActive, not recruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07648225 · 600 participants (planned) · Start Sep 4, 2026 · Primary completion Sep 29, 2027
Drug: UBT251 Injection 4.0 mg; UBT251 Injection 6.0 mg and 2 more · For: Obesity & Overweight
Sites: Beijing, China
- Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone(UNIGUIDE-1)Pivotal-lookingRecruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07659574 · 360 participants (planned) · Start Sep 7, 2026 · Primary completion Sep 24, 2027
Drug: UBT251 Injection 2.0 mg; UBT251 Injection 4.0 mg and 4 more · For: Type 2 Diabetes
Sites: Changsha, China
- A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or ObesityPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07395687 · 333 participants (planned) · Start Feb 2, 2026 · Primary completion Jan 14, 2027
Drug: UBT251; Placebo · For: Overweight; Obesity
Sites: Cypress, California; Overland Park, Kansas; Montreal, Canada
- A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesPivotal-lookingRecruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07668388 · 300 participants (planned) · Start Jun 22, 2026 · Primary completion Oct 4, 2027
Drug: UBT251; UBT251 Placebo and 2 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Fountain Valley, California; Long Beach, California · 70 sites in all
- UBT251 Injection Phase II (Type 2 Diabetes Mellitus) StudyPivotal-lookingCompleted
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07163624 · 211 participants · Start Mar 22, 2025 · Primary completion Nov 21, 2025
Drug: UBT251 Injection 2.0 mg and UBT251 Injection Placebo; UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo and 3 more · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Zhuhai, China
- UBT251 Injection Phase II Study (Overweight or Obesity)Pivotal-lookingCompleted
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07177469 · 205 participants · Start Mar 14, 2025 · Primary completion Oct 22, 2025
Drug: UBT251 Injection 2.0 mg and UBT251 Injection Placebo; UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo and 2 more · For: Obesity &Amp; Overweight
Sites: Changsha, China
- UBT251 Injection Phase II Clinical Study (CKD)Pivotal-lookingRecruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07134335 · 180 participants (planned) · Start Sep 1, 2025 · Primary completion Jul 11, 2030
Drug: UBT251; UBT251 and 1 more · For: Obesity &Amp; Overweight; Chronic Kidney Disease
Sites: Beijing, China
- A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)Pivotal-lookingRecruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07145151 · 156 participants (planned) · Start Sep 30, 2025 · Primary completion Jun 4, 2027
Drug: UBT251; Placebo · For: Metabolic Dysfunction-associated Steatohepatitis (MASH)
Sites: Beijing, China
- UBT251 Injection Phase Ⅲ Study (OSA-NPAP)Pivotal-lookingNot yet recruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07767942 · 150 participants (planned) · Start Dec 1, 2026 · Primary completion Sep 2028
Drug: UBT251; UBT251 and 1 more · For: Obstructive Sleep Apnea, Obesity
Newest research
PubMed records naming it or its code names, newest first.
- Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study.
Yang GP, Liu YX, Xie JL, et al. · Diabetes Obes Metab 2026
- UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial.
Zhou Z, Shi X, Jiang S, et al. · Cell Metab 2026
- UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.
Zhou Z, Cheng Z, Jin P, et al. · Cell Metab 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.